Psychedelic Drugs Market to Surge to USD 4.6 Billion by 2030, Driven by Therapeutic Potential and Rising Mental Health Awareness
January 24, 2024 10:59 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Psychedelic Drugs Market 2030 by Source, Drug Type, Distribution Channel and Region - Partner & Customer Ecosystem Competitive Index &...
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
January 24, 2024 09:35 ET
|
PharmAla Biotech
PharmAla recieved a new OTCQB ticker, MDXXF.
Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence
January 19, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Health granted amendment to its Health Canada Controlled Drugs and Substances Licence.
MAPS Unveils Improved Fiscal Sponsorship Program, Empowering Innovators in the Psychedelic Movement
January 16, 2024 16:27 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
To date, MAPS has supported nearly 70 organizations worldwide to advance charitable projects in the psychedelic movementCurrently, MAPS serves as a fiscal sponsor for 10 organizations in the newly...
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
January 08, 2024 08:55 ET
|
PharmAla Biotech
PharmAla announces that its novel P1 molecule has been accepted by USPTO to its accelerated "Patent Prosecution Highway"
Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats
January 03, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Health Granted Precursor Licence for 3,4-Methylenedioxyphenyl-2-propanone (“MDP2P”), the precursor used in the chemical synthesis of MDMA.
PharmAla Files Audited Financials for Year Ending August 31, 2023
December 29, 2023 16:00 ET
|
PharmAla Biotech
PharmAla releases audited year-end financials for the period ended August 31st.
Sunstone Therapies Announces Publication of Positive Phase 2 Study Results in Cancer
December 18, 2023 07:00 ET
|
Sunstone Therapies
Sunstone Therapies Announces Publication of Positive Phase 2 Study Results in Cancer Phase 2 trial demonstrated the safety and efficacy of psilocybin-assisted group therapy for...
Beckley Academy Welcomes New Faculty for 2024 Psychedelic Therapy Practitioners Courses
December 14, 2023 09:00 ET
|
Beckley Academy
Beckley Academy Welcomes New Faculty for 2024 Psychedelic Therapy Practitioners Courses
Sunstone Therapies Celebrates Three Year Anniversary With More Than 100 Psychedelic-Assisted Therapy Treatments Completed
December 14, 2023 07:00 ET
|
Sunstone Therapies
Sunstone Therapies Celebrates Three Year Anniversary With More Than 100 Psychedelic-Assisted Therapy Treatments Completed Sunstone has developed an unrivalled expertise and experience in...